Clinical Trial Detail

NCT ID NCT04336943
Title Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
Recruitment Not yet recruiting
Gender male
Phase Phase II
Variant Requirements Yes
Sponsors University of Washington
Indications

prostate adenocarcinoma

Therapies

Durvalumab + Olaparib

Age Groups: senior adult

Additional content available in CKB BOOST